Compare GSUN & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSUN | IMRN |
|---|---|---|
| Founded | 1997 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7M | 12.0M |
| IPO Year | 2022 | N/A |
| Metric | GSUN | IMRN |
|---|---|---|
| Price | $1.24 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 125.9K | ★ 1.3M |
| Earning Date | 02-12-2026 | 08-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,314,724.00 | $4,777,422.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 526.22 | 48.63 |
| 52 Week Low | $0.98 | $0.91 |
| 52 Week High | $5.25 | $2.48 |
| Indicator | GSUN | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 39.76 | 25.01 |
| Support Level | $0.98 | $0.91 |
| Resistance Level | $1.31 | $1.78 |
| Average True Range (ATR) | 0.14 | 0.11 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 43.75 | 3.67 |
Golden Sun Health Technology Group Ltd is a holding company. Along with its subsidiaries, it is engaged in the provision of education services and e-commerce business in the People's Republic of China. It offers tutorial centers for children and adults, one educational company that partners with high schools to offer language classes to their students, and one logistics company that provides logistics and consulting services. It has also established its wellness brands and an e-commerce platform to promote and sell wellness products. The company operates in the following segments; Education, which generates maximum revenue, and E-commerce.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.